All In Biotech

Drug Trial Radar · NCT02353949

Investigating the Clinical Consequences of Flutemetamol-PET-scanning

Last checked: Nov 20, 2026Latest source record: Jan 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

11

Actual

Start

May 2015

Primary completion

Dec 10, 2019

Study completion Dec 10, 2019

Sponsor

Lead sponsor
University of ZurichAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
ETH Zurich
First posted
Feb 3, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study examines subjects where there might be an indication for Amyloid-PET according to the Criteria defined by the Amyloid Imaging Task Force. In these subjects the impact of a Flutemetamol (Vizamyl)-Positron-Emission-Tomography -Scan (PET) on clinical management and disease course will be studied over 6 months.

Conditions

  • Mild Cognitive Impairment
  • Alzheimer's Disease
  • Dementia

Interventions

  • Flutemetamol (Vizamyl)Drug

    PET-MR Scan using the radiotracer Flutemetamol (Vizamyl) for diagnostic purpose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change of ADAS-cog 11 score compared to pre-treatment assessment in Flutemetamol positive subjects with a postscan diagnosis of AD and start of cholinesterase inhibitors as standard treatment.Time frame: Three months after initiation of standard treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Zurich, Institute for Regenerative Medicine, Center for Prevention and Dementia Therapy

    Schlieren, Canton of Zurich, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.